Chris BUYSE

Chris BUYSE

Biotech Expert, Fund+ Managing Partner

Chris BUYSE was CFO at ThromboGenics NV from September 2006 until June 2014. He has 25 years of experience in international company finance and in running and establishing best financial practice. He is currently serving as an independent Board Member of a few companies, mostly active in life sciences such as Celyad, Bone Therapeutics, Iteos and Bioxodes.

We are Theodorus,

THE ULB SPIN-OFF FUND
AND WE ARE LOOKING FORWARD
TO MEETING YOU!